HRT Financial’s Karyopharm Therapeutics KPTI Stock Holding History

HRT Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$389K	Buy	+70,000	New	+$534K	﹤0.01%	2701

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

HRT Financial's KPTI Position: Q3 2024 in Review

HRT Financial sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 9,836 shares — an estimated $128K sold.

HRT Financial first reported a position in KPTI in Q4 2020 and held it in 5 quarters. The position peaked at $1.6M in Q4 2021. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

HRT Financial reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
HRT Financial sold 9,836 Karyopharm Therapeutics shares in Q3 2024, an estimated $128K.
HRT Financial first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 5 quarters.
HRT Financial's Karyopharm Therapeutics position peaked at $1.6M in Q4 2021.
91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on HRT Financial's 13F filing for Q3 2024, filed 12 Nov 2024.